Week In Review: China Life Science Deals Total $550 Million
December 09, 2017 at 16:13 PM EST
Pfizer (NYSE: PFE) signed a $226 million agreement for China/Asian rights to Cresemba® (isavuconazole), an antifungal drug and Everest Medicines announced a $224 million partnership with San Diego's Arena Pharma.
